In this review:
Cytoreductive nephrectomy in metastatic papillary RCC
Crizotinib in advanced papillary RCC type 1
Atezolizumab + bevacizumab in mRCC
Erdafitinib in urothelial carcinoma with FGFR alterations
Serum microRNA prediction of post-chemotherapy viable disease
Perioperative chemotherapy vs surveillance in UTUC
Abiraterone vs enzalutamide in metastatic CRPC
Enzalutamide for non-metastatic CRPC
Apalutamide for non-metastatic CRPC
Androgen suppression ± zoledronate for locally advanced prostate cancer
Please login below to download this issue (PDF)